Bryan Johnson Before and After: A Clinical Analysis of His Longevity Protocol Results

What Does Bryan Johnson Actually Look Like Before and After?

Johnson's visual transformation is measurable, not merely anecdotal. Comparing publicly available photographs from 2018 (pre-Blueprint) to 2024 shows a leaner facial structure, reduced periorbital puffiness, and visibly improved skin texture. His body weight dropped from approximately 193 lb to 161 lb, a reduction of roughly 32 lb sustained over three years.

These visual changes align with what any combination of aggressive caloric restriction, high-volume exercise, and improved sleep architecture would predictably produce. The question is whether the photographic changes exceed what is achievable by diet and exercise alone, and what the biomarker data actually show underneath the optics.

Skin and Facial Appearance Changes

Dermatological aging is partly driven by glycation end-products, UV damage, and collagen cross-linking. Johnson's published protocol includes nightly topical tretinoin (0.1%), daily broad-spectrum SPF 50+ sunscreen, and oral collagen peptides. Tretinoin's evidence base is strong: a randomized controlled trial published in the Journal of the American Academy of Dermatology (N=204) showed 0.1% tretinoin applied over 48 weeks produced statistically significant reductions in facial wrinkles and hyperpigmentation versus vehicle control [1]. His reduced periorbital fullness is consistent with a drop to 6-7% body fat and sustained caloric restriction.

Body Composition Changes

DEXA scan data Johnson has published show a shift from an estimated 20-22% body fat in early adulthood to approximately 6-7% body fat currently. That degree of leanness correlates with reduced visceral adiposity. Visceral fat is an independent predictor of all-cause mortality: a prospective cohort analysis of 7,637 subjects in the Multi-Ethnic Study of Atherosclerosis found each unit increase in visceral adipose tissue was associated with a 1.45-fold higher risk of cardiovascular events [2].

The Blueprint Protocol: What He Is Actually Taking

Johnson's team publishes his full stack at blueprint.bryanjohnson.com. The prescription component is the most clinically significant portion, because it sits well outside standard preventive medicine guidelines for a 47-year-old without diagnosed metabolic disease.

Rapamycin

Johnson takes rapamycin (sirolimus) 13 mg once weekly, a dosing pattern informed by the Interventions Testing Program (ITP) at the National Institute on Aging, which found that rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% even when started at age equivalent to 60 human years [3]. The FDA has approved rapamycin for organ transplant rejection prophylaxis, not anti-aging. Its mTORC1 inhibition reduces anabolic signaling, which may impair muscle protein synthesis at higher doses. No randomized controlled trial in humans has demonstrated longevity extension with rapamycin, and the optimal dose for a non-immunocompromised human remains unknown.

Metformin and Acarbose

Metformin 1,500 mg/day and acarbose 200 mg with meals are both FDA-approved anti-diabetic agents. The TAME (Targeting Aging with Metformin) trial, a multi-center RCT funded by the American Federation for Aging Research (N=3,000, ongoing), is specifically designed to test whether metformin delays aging-related outcomes. Results are expected around 2027 [4]. Johnson takes acarbose partly because ITP data showed acarbose extended median lifespan in male mice by 22% [5]. Neither drug is approved for longevity indications in otherwise healthy adults.

Testosterone, DHEA, and Thyroid Hormone

Johnson uses low-dose testosterone (testosterone cypionate), DHEA 25 mg/day, and supplemental thyroid hormone (T3/T4). His testosterone levels are managed to keep total testosterone in the high-normal range, approximately 800-1,000 ng/dL. The Endocrine Society's 2018 clinical practice guideline states that testosterone therapy is indicated for men with confirmed hypogonadism (morning total testosterone consistently <300 ng/dL on two measurements) and relevant symptoms [6]. Johnson has not publicly confirmed a hypogonadism diagnosis, which places his testosterone use in an evidence-light zone for men without that diagnosis.

The 111-Pill-Per-Day Supplement Stack

Selected compounds with meaningful peer-reviewed support include:

• NMN (nicotinamide mononucleotide) 2,000 mg/day: A phase I RCT (N=10) published in Cell Metabolism showed oral NMN raised blood NAD+ levels dose-dependently with no serious adverse events [7].
• Lycopene 30 mg/day: A meta-analysis of 14 RCTs found lycopene supplementation significantly reduced LDL oxidation (P<0.001) [8].
• Omega-3 fatty acids 3.6 g EPA/DHA daily: REDUCE-IT (N=8,179) showed 4 g/day icosapentaenoic acid reduced major cardiovascular events by 25% versus placebo over 4.9 years [9].
• Lithium 1 mg/day: Observational data from 45,000 Danish subjects found communities with higher natural lithium in drinking water had lower all-cause mortality [10].

Biomarker Data: What His Published Numbers Actually Show

Epigenetic Age Clocks

Johnson's most frequently cited claim is a biological age approximately 5.1 years younger than his chronological age on the Levine PhenoAge clock. Epigenetic clocks measure DNA methylation patterns correlated with aging. The GrimAge clock, considered the most mortality-predictive, reportedly places him at a lower risk profile as well. A 2022 study in Aging Cell (N=128) showed multi-component lifestyle interventions could reduce methylation age by a mean of 3.23 years over eight weeks [11], so meaningful short-term shifts are biologically plausible. The clinical significance of a 5-year epigenetic age reduction in preventing actual mortality events has not been demonstrated in any RCT.

VO2 Max

A VO2 max of 58.7 mL/kg/min is genuinely exceptional for a 47-year-old male. The American Heart Association's 2016 scientific statement identifies cardiorespiratory fitness as a stronger predictor of mortality than traditional cardiovascular risk factors [12]. Men aged 45-49 with a VO2 max above 55 mL/kg/min fall in the "superior" category and have roughly 45% lower all-cause mortality versus those in the "low" category at the same age.

Coronary Artery Calcification (CAC)

Johnson's CAC score is 0 (Agatston units), which is favorable. A CAC score of 0 in a man approaching age 50 places him below the 15th percentile of risk for that age group per MESA data. The AHA/ACC 2019 cholesterol guidelines recommend considering CAC scoring in intermediate-risk patients when treatment decisions are uncertain [13].

Telomere Length

His published telomere length data show values in the top 1% for age. Telomere length as a biomarker of longevity is controversial: a large Mendelian randomization study (N=472,174) published in BMJ found genetically longer telomeres were associated with higher risk of several cancers, underscoring that longer is not simply better [14].

A Clinical Framework for Interpreting His "Before and After"

The table below separates Johnson's reported outcomes into three tiers based on strength of supporting evidence.

| Outcome | Reported Change | Evidence Tier | Notes | |---|---|---|---| | Body composition | 193 lb to 161 lb; 6-7% body fat | Tier 1: Well-supported | Achievable with caloric restriction + exercise alone | | VO2 max 58.7 mL/kg/min | Top 1.5% for age | Tier 1: Well-supported | Consistent with reported 1+ hour daily exercise | | Skin texture improvement | Visibly reduced wrinkles | Tier 1 (for tretinoin) | Tretinoin RCT evidence is solid | | PhenoAge clock: -5.1 years | Biological age reduced | Tier 2: Plausible, not proven causal | No RCT confirms mortality benefit of clock improvement | | Telomere length top 1% | Above age average | Tier 3: Uncertain significance | Mendelian randomization shows non-linear risk | | Rapamycin lifespan extension | Unknown in humans | Tier 3: Extrapolated from mice | No human longevity RCT data | | NMN NAD+ restoration | Raises NAD+ in blood | Tier 2: Phase I only | Clinical longevity endpoints not yet demonstrated |

The photographic before-and-after is real. The biological mechanism driving it, however, is almost certainly dominated by diet, exercise, and sleep, not the more exotic pharmaceutical interventions. Disentangling the signal from rapamycin, NMN, or acarbose in a single-subject N=1 protocol is statistically impossible.

What the Average Person Can Realistically Extract From Blueprint

Johnson's protocol costs approximately $2 million per year. That price tag is irrelevant to almost everyone. The interventions with the highest evidence-to-cost ratios, accessible without a team of 30 physicians, are the following.

Diet and Caloric Intake

Johnson eats 1,977 kcal/day from a plant-forward diet with no added sugar, no alcohol, and meals completed by 11 a.m. (a compressed eating window). Caloric restriction extending lifespan is supported by decades of animal data and a 2022 RCT (CALERIE-2, N=220) that showed a 11.9% sustained caloric restriction in non-obese humans produced significant reductions in cardiometabolic risk factors over 24 months without adverse effects on lean mass [15].

Exercise

His reported exercise regimen is approximately 60-75 minutes of mixed resistance and aerobic training per day. Meta-analyses consistently show 150-300 minutes of moderate-to-vigorous aerobic activity per week reduces all-cause mortality by approximately 30-35% versus sedentary controls [16]. This is free.

Sleep Optimization

Johnson reports optimizing for 8.5 hours of time in bed with consistent sleep and wake times. A prospective cohort study of 21,000 Finnish twins found sleeping fewer than 7 hours per night was associated with a 26% higher all-cause mortality risk in men versus those sleeping 7-8 hours [17].

Actionable Biomarker Testing

Testing that a primary care physician can order today and that mirrors Johnson's monitoring approach includes fasting glucose, HbA1c, lipid panel with LDL particle size, hsCRP, homocysteine, testosterone (morning), TSH, free T4, CBC, and comprehensive metabolic panel. Coronary artery calcium scoring is available for $100-200 out-of-pocket at most imaging centers for adults over age 40.

Honest Limitations of Johnson's N=1 Experiment

Confounding Is Unavoidable

With no control arm, no randomization, and simultaneous introduction of 50-plus interventions, attributing any single biomarker change to any specific drug or supplement is scientifically impossible. This is not a criticism of Johnson personally; it is a structural limitation of self-experimentation regardless of how rigorously tracked.

Selection Bias in Reporting

Johnson and his team control what data gets published. Negative or null results may be underreported. Publication bias of this kind inflates apparent benefit in any self-reported health optimization account.

Generalizability

Johnson has access to resources, time, and monitoring that make his protocol unreplicable for most people. Applying his framework wholesale without medical supervision could cause harm, particularly regarding rapamycin (immunosuppression risk), testosterone (suppression of endogenous production), and acarbose (GI side effects, hypoglycemia risk in certain contexts).

The Longevity-Performance Trade-off

Running at 6-7% body fat and training 60+ minutes daily is physically demanding. The Endocrine Society notes that very low body fat in men may impair hormonal function and immune response over time. Whether Johnson's protocol extends healthspan in the long term, or merely optimizes short-term biomarkers at a biological cost that will manifest later, is genuinely unknown.

What Board-Certified Physicians on the HealthRX Team Observe

The Endocrine Society's 2023 Clinical Practice Guideline on hypogonadism states: "We recommend against routine testosterone treatment of men with age-related decline in testosterone who do not meet diagnostic criteria for hypogonadism" [6]. That single sentence captures the core tension in Johnson's pharmaceutical stack: interventions validated in diseased populations are being extrapolated to a healthy individual, with the assumption that moving biomarkers toward a younger range will translate to longer life.

That assumption may prove correct. It has not yet been tested in a controlled human trial. Johnson himself acknowledges this, framing Blueprint explicitly as an experiment rather than a proven protocol.

The photographic evidence is persuasive precisely because the interventions with the clearest visual impact, body composition change, skin-care actives, and reduced inflammation from diet, are the ones with the strongest underlying evidence base.